Allarity Therapeutics (ALLR) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Allarity Therapeutics (ALLR) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 42.2% versus a loss of 85.3%. Radiopharm Theranostics is the larger company by market cap ($16.2 million vs $15.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | RADX |
|---|---|---|
| Share price | $0.9819 | $1.11 |
| Market cap | $15.62M | $16.20M |
| 1-day change | -0.21% | -3.48% |
| YTD return | -9.08% | -78.74% |
| 1-year return | -42.24% | -85.27% |
| EPS (TTM) | $-0.79 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.84 | $16.25 |
| 52-week low | $0.769 | $1.00 |
| Distance from 52-week high | -46.64% | -93.17% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1020.28% | +1430.63% |
| Average volume | 90.63K | 84.62K |
| Shares outstanding | 15.91M | 14.59M |
| Employees | 7 | 14 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLR has outperformed RADX by 43.0 percentage points over the past year.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Healthcare · Biotechnology · 7 employees
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Healthcare · Biotechnology · 14 employees
ALLR vs RADX FAQ
Which is bigger, Allarity Therapeutics or Radiopharm Theranostics?
Radiopharm Theranostics (RADX) is larger, with a market capitalization of $16.20M compared with $15.62M for Allarity Therapeutics (ALLR).
Which stock has performed better over the past year, ALLR or RADX?
ALLR returned -42.24% over the past 12 months, compared with -85.27% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.